Related Experiment Video

Updated: Jun 8, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statin alternatives for the treatment of hypercholesterolemia - a safety evaluation

Weiwei Zeng¹, Brian Tomlinson²

¹Department of Pharmacy, Shenzhen Longgang Second People's Hospital, Shenzhen, China.

Expert Opinion on Drug Safety

|November 1, 2024

Insights

Statin alternatives like ezetimibe, PCSK9 inhibitors, and bempedoic acid offer safe options for managing high cholesterol when statins are not tolerated. These treatments generally have good safety profiles with minimal side effects.

Area of Science:

Cardiology
Pharmacology
Metabolic Disorders

Background:

Statins are primary treatments for lowering low-density-lipoprotein cholesterol (LDL-C) and preventing cardiovascular events.
Some patients experience intolerance to statins, necessitating alternative therapies.
Hypercholesterolemia management requires effective and safe treatment options.

Purpose of the Study:

To review the safety of alternative hypercholesterolemia treatments.
To summarize published literature on non-statin lipid-lowering drugs.
To provide an overview of the safety profiles of emerging cholesterol-lowering medications.

Main Methods:

Literature search of PubMed for safety data on statin alternatives.
Review of clinical trial data and published studies.
Analysis of adverse event profiles for key alternative medications.

Main Results:

Ezetimibe, PCSK9 inhibitors (evolocumab, alirocumab, inclisiran), and bempedoic acid demonstrate excellent safety.
These alternatives are not linked to muscle symptoms or increased diabetes risk.
PCSK9 inhibitors may cause mild injection site reactions; bempedoic acid can increase uric acid levels.

Conclusions:

Statin alternatives possess favorable safety profiles, making them viable options for patients intolerant to statins.
Choice of alternative is often guided by cost, availability, and LDL-C reduction goals rather than safety concerns.
These drugs offer effective lipid-lowering with distinct safety considerations for specific patient populations.

Read full analysis

Abstract

Introduction:

Statins are well established as the first-line treatment to reduce low-density-lipoprotein cholesterol (LDL-C) and cardiovascular (CV) events, but some patients are unable to tolerate effective doses or sometimes any dose of statins and alternative treatments may be required.

Areas Covered:

In this review we summarize the relevant published literature obtained from a PubMed search on the safety of statin alternatives for the treatment of hypercholesterolemia.

Expert Opinion:

The main alternatives to statins are ezetimibe, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab, alirocumab, and inclisiran, and the recently approved bempedoic acid. These have all shown an excellent safety profile and have not been associated with skeletal muscle symptoms or with increased risk of new onset diabetes and they have no major drug interactions. The injectable PCSK9 inhibitors are associated with a small increase in injection site reactions which are usually of mild or moderate intensity. Bempedoic acid is associated with a small increase in plasma uric acid and slightly increased frequency of episodes of gout in susceptible subjects. The cost and availability and the degree of lowering of LDL-C required are more likely to determine the choice of statin alternatives than the safety issues.

Keywords:

Alirocumab bempedoic acid evolocumab ezetimibe inclisiran proprotein convertase subtilisin/kexin type 9 inhibitors statin alternatives

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Cholesterol: Significance and Regulation

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Lipids: Dietary Sources and Requirements

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Articles linked to this work by shared authors, journal, and citation graph.

Impact of diagnosis-related group-based bundled payment on hospitalization costs and clinical outcomes in total hip arthroplasty: an interrupted time series analysis from Wenzhou, China.

Frontiers in public health·2026

MVGCL: Noise-Robust Multi-Source Similarity Fusion and Type-Aware Dual-Pathway Learning for Drug Repositioning.

Journal of chemical information and modeling·2026

Integrated lipidomic and transcriptomic analyses reveal stage-specific hepatic lipid remodeling during GCRV-II infection in grass carp (Ctenopharyngodon idella).

Fish & shellfish immunology·2026

Real-world variability and factors associated with individual low-density-lipoprotein cholesterol response to different doses of atorvastatin, rosuvastatin, and simvastatin in 28,647 Chinese patients.

Atherosclerosis·2026

Safety, immunogenicity, and broad-spectrum protective efficacy of a naturally attenuated GCRV-II strain against viral and bacterial challenges in grass carp.

Fish & shellfish immunology·2026

The three-HOMO-site rule: a frontier-orbital descriptor for low-barrier multi-proton synchronous hopping.

Physical chemistry chemical physics : PCCP·2026

See all related articles